大洋洲 · 新闻 · The Courier-Mail

Health Check: CSL places $500m-plus bet on rare kidney and liver disease drug candidate

来源：The Courier-Mail · 澳大利亚 10 小时前

CSL (ASX:CSL) has ramped up its research and development efforts via a US$355 million ($515m)-plus drug development collab with private Swiss group Alentis Therapeutics.

在 The Courier-Mail 阅读全文登录后可收藏

MediaNews 仅展示媒体发布的标题和摘要，全文请在出版方网站阅读。 (www.couriermail.com.au)

Health Check: CSL places $500m-plus bet on rare kidney and liver disease drug candidate

推荐阅读

Yemeni govt forces advance near key strait in offensive

Peter and Maria were mourned by people who loved them. So how did they end up in unmarked communal graves?

The ‘loneliest place on Earth’ is a spectacular NZ spot most Australians miss

The ‘loneliest place on Earth’ is a spectacular NZ spot most Australians miss

The ‘loneliest place on Earth’ is a spectacular NZ spot most Australians miss

The best text to speech model, and what it costs you to hear it

Health Check: CSL places $500m-plus bet on rare kidney and liver disease drug candidate

分享

推荐阅读

Yemeni govt forces advance near key strait in offensive

Peter and Maria were mourned by people who loved them. So how did they end up in unmarked communal graves?

The ‘loneliest place on Earth’ is a spectacular NZ spot most Australians miss

The ‘loneliest place on Earth’ is a spectacular NZ spot most Australians miss

The ‘loneliest place on Earth’ is a spectacular NZ spot most Australians miss

The best text to speech model, and what it costs you to hear it